Page 1204 - Basic _ Clinical Pharmacology ( PDFDrive )

1190 Index

Antifungal agents, systemic, 853–860 case study of, 1058, 1067 amantadine and rimantadine, 892
allylamine, 861, 861t categories of, 175–176, 176f investigational, 892
amphotericin B, 853–854, 861t clinical pharmacology of, 189 oseltamivir and zanamivir, 891–892
azoles chronic hypertension, alpha-receptor Anti-integrin therapy, 1112
description of, 856–859, 861t antagonists, 161 Antilymphocyte globulin (ALT), 990
drug interactions of, 1159t–1160t hypertensive emergencies, 190–191 Antimetabolites, 957–961
echinocandins, 859–860, 861t outpatient therapy, 189–190 antifolates
flucytosine, 855f, 856, 861t diuretics, 175, 176–178, 191t methotrexate, 957, 958t
oral, for mucocutaneous infections mechanisms of action and pemetrexed, 957–958, 958t
griseofulvin, 860 hemodynamic effects of, 177 pralatrexate, 958–959
terbinafine, 860, 861t toxicity of, 178 deoxycytidine analogs
Antifungal agents, topical use of, 177–178, 179t cytarabine, 958t, 960
allylamines, 860–861, 861t in elderly, 1063 gemcitabine, 958t, 960
azoles, 860–861 ganglion-blocking agents, 181 development of, 957
nystatin, 860 hypertension and blood pressure fluoropyrimidines
Antigen-presenting cells (APCs), 979, 979f regulation by, 173–175, 174f, capecitabine, 958t, 959
Antihelminthics 175f. See also Hypertension 5-fluorouracil, 958t, 959
albendazole, 938–940, 939t preparations available, 193t purine antagonists
bithionol, 939t, 940 sites of action of, 175, 176f cladribine, 958t, 961
diethylcarbazine citrate, 939t, 940–941 sympathoplegics, 176, 176f, 178–182 fludarabine, 958t, 961
ivermectin, 939t, 941–942 adrenergic neuron-blocking agents 6-thiopurines, 958t, 960–961, 961f
mebendazole, 939t, 942 guanethidine, 181–182, 191t Antimicrobial agents, 793–916, 794f.
metrifonate, 939t, 943 reserpine, 179t, 182, 191t See also specific agents and types
niclosamide, 939t, 943 alpha-adrenoceptor blockers, other, development of, 904
oxamniquine, 939t, 943–944 184 drug combinations of
piperazine, 939t, 944 beta-adrenoceptor blocking agents, antagonism in, 912–913
praziquantel, 939t 179t, 182–183. See also rationale for, 912
preparations available, 939t, 946 b-receptor antagonist drugs synergism in, 912–913
pyrantel pamoate, 939t esmolol, 183 drug toxicity management for,
thiabendazole, 939t, 946 centrally acting, 179t, 179–180, 191t 907t–908t, 912
Antihepatitis agents, 884–891 clonidine, 179t, 179–181 in elderly, 1064
hepatitis B guanabenz and guanfacine, 180 empiric therapy with, 905–906,
adefovir dipivoxil, 886 methyldopa, 179, 179t 907t–909t
entecavir, 886 preparations of, 193t approach to, 905
fundamentals of, 884 vasodilators, 178f, 179t, 184–187, 192t choice of, 905–906
lamivudine, 886–887 calcium channel blockers, 179t, microbiology etiology in, 907t–908t
telbivudine, 887 186–187, 193t site of infection in, 909t
tenofovir, 887 diazoxide, 186, 192t etiologic agent and indications for, 905
hepatitis C, 887–891 direct, 176 infections of known etiology treated
fundamentals of, 887 fenoldopam, 186, 192t with, 906–911
polymerase inhibitors, 889 hydralazine, 179t, 184–185 misuse of, 793
protease inhibitors, 889, 890f mechanisms and sites of action of, Antimicrobial prophylaxis
simeprevir, 890–891 184, 184t nonsurgical, 914, 915t, 916
sofosbuvir, 889 minoxidil, 179t, 185 NRC wound classification criteria and,
ribavirin, 891 preparations available, 192t, 193t 914b
interferon alfa, 884t, 884–885, sodium nitroprusside, 185–186, surgical, 913–914, 914t
893t–894t 192t Antimuscarinic drugs, 124. See Muscarinic
Antihistamines, 281–285, 1129t Anti-IgE monoclonal antibodies, asthma receptor blockers (antagonists)
Antihypertensive agents, 173–193, treated with, 357, 360, 362t Antimycobacterial drugs, 842–852,
191t–192t. See also specific types Anti-IL-5 therapy, 357, 363t 851t
angiotensin inhibitors, 176, 187–189 Anti-inflammatory agents, 642. See also atypical mycobacteria, 849–850,
angiotensin-converting enzyme specific types 850t
inhibitors, 179t, 187–189, 192t, dermatologic, 1079–1082 leprosy
193t corticosteroids, topical, 1079–1081, clofazimine, 851
angiotensin receptor blockers, 179t, 1080t, 1081t dapsone and other sulfone, 850
189, 192t, 193t tar compounds, 1082 rifampin, 851, 851t
mechanisms and sites of action of, in elderly, 1064 tuberculosis, 842–849. See also
187, 188f Anti-influenza agents, 891–892 Tuberculosis drugs